28 results on '"Salcedo, Meghan"'
Search Results
2. Sustained Minimal Residual Disease Negativity in Multiple Myeloma is Associated with Stool Butyrate and Healthier Plant-Based Diets.
3. Association of patient activity bio-profiles with health-related quality of life in patients with newly diagnosed multiple myeloma: a prospective observational cohort study
4. Colesevelam for Lenalidomide Associated Diarrhea in Patients with Multiple Myeloma
5. Using MALDI-TOF mass spectrometry in peripheral blood for the follow up of newly diagnosed multiple myeloma patients treated with daratumumab-based combination therapy
6. Supplementary fig 1 from Sustained Minimal Residual Disease Negativity in Multiple Myeloma is Associated with Stool Butyrate and Healthier Plant-Based Diets
7. A Phase 2 Trial of Colesevelam for Lenalidomide-Associated Diarrhea
8. A short course of daratumumab in patients with multiple myeloma and minimal residual disease after induction therapy
9. Sustained Minimal Residual Disease Negativity in Multiple Myeloma is Associated with Stool Butyrate and Healthier Plant-Based Diets
10. Association of Patient Activity Bio-Profiles with Health-Related Quality of Life: A Prospective Trial Using Mobile Wearables in Newly Diagnosed Multiple Myeloma Patients
11. Safety and Effectiveness of Weekly Carfilzomib, Lenalidomide, Dexamethasone, and Daratumumab Combination Therapy for Patients With Newly Diagnosed Multiple Myeloma
12. Phase I Study of Selinexor, Ixazomib, and Low-dose Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
13. Using mobile wearables to establish sleep bioprofiles in newly diagnosed multiple myeloma (MM) patients.
14. Tailored treatment to MRD response: A phase I/II study for newly diagnosed multiple myeloma patients using high dose twice‐weekly carfilzomib (45 and 56 mg/m 2 ) in combination with lenalidomide and dexamethasone
15. Long-Term Sustained Minimal Residual Disease (MRD) Negativity in Patients with Multiple Myeloma Treated with Continuous Lenalidomide Maintenance Therapy: A Clinical and Correlative Phase 2 Study
16. Weekly Carfilzomib, Lenalidomide, Dexamethasone and Daratumumab (wKRd-D) Combination Therapy in Newly Diagnosed Multiple Myeloma: Final Results from a Clinical and Correlative Phase 2 Study
17. Association of Patient Activity Bioprofiles with Hrqol and Clinical Responses: A Prospective Novel Trial Using Mobile Wearables in Newly Diagnosed Multiple Myeloma Patients
18. Tailored treatment to MRD response: A phase I/II study for newly diagnosed multiple myeloma patients using high dose twice‐weekly carfilzomib (45 and 56 mg/m2) in combination with lenalidomide and dexamethasone.
19. Long-Term Sustained Minimal Residual Disease (MRD) Negativity in Multiple Myeloma Patients Treated with Lenalidomide Maintenance Therapy: A Clinical and Correlative Phase 2 Study
20. Weekly Carfilzomib, Lenalidomide, Dexamethasone and Daratumumab (wKRd-D) Combination Therapy Provides Unprecedented MRD Negativity Rates in Newly Diagnosed Multiple Myeloma: A Clinical and Correlative Phase 2 Study
21. Minimal residual disease negativity in multiple myeloma is associated with intestinal microbiota composition
22. Ixazomib and dexamethasone in high risk smoldering multiple myeloma: A clinical and correlative pilot study.
23. Intestinal Microbiota Composition Is Associated with Minimal Residual Disease Negativity in Patients with Multiple Myeloma
24. Bone Marrow-Based and Longitudinal Blood-Based MRD Tracking in Newly Diagnosed Multiple Myeloma Patients Treated with Daratumumab, Carfilzomib, Lenalidomide and Dexamethasone (DKRd): A Correlative and Clinical Phase II Study
25. Continuous Mobile Wearable Bio-Monitoring of Newly Diagnosed Multiple Myeloma Patients Undergoing Initial Chemotherapy
26. MRD-Response Driven Phase I/II Study for Newly Diagnosed Multiple Myeloma Patients Using Higher Doses of Twice-Weekly Carfilzomib (45 and 56 mg/m2) in Combination with Lenalidomide and Dexamethasone
27. Ixazomib and dexamethasone in high risk smoldering multiple myeloma: a clinical and correlative pilot study.
28. Colesevelam for Lenalidomide Associated Diarrhea in Patients with Multiple Myeloma.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.